1. HBW Insight
  2. >>Health
  3. >>Rx-to-OTC Switch

Norway Model Offers Key To Unlock More Complex Switches

 
• By Tom Gallen

Norway's move to encourage more innovative Rx-to-OTC switches has begun to bear fruit with the recent reclassification of Pfizer's Viagra. The country's decision to introduce a new non-prescription drug category to promote switching can be used as a model for securing a new wave of more complex switches elsewhere around the world.

Norway flag

Norway’s decision to switch Pfizer’s blockbuster drug Viagra from prescription-to-OTC status last month means it has joined a very select group of countries globally that have reclassified erectile dysfunction treatment sildenafil. Just Poland, New Zealand and the UK have up until now allowed sildenafil to be supplied without a prescription.

By succeeding with its Viagra switch, Pfizer became the first firm to benefit from a recent change of law in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rx-to-OTC Switch

The Global Allergy Market In 2025: ‘Growth Is Back, But Not Like Before’

 
• By David Ridley

The global allergy market is “expanding again but on new terms, driven by a mix of regional strength, evolving consumer behaviors, and an increasingly diverse competitive field,” according to the latest IQVIA Consumer Health analysis.

Japan Switches Rohto’s Algard Epinastine Eye Drops, Approves OTC Black Cohosh For Menopause

 
• By David Ridley

Japan’s Ministry of Health, Labor and Welfare continues to widen access to non-prescription medicines with another Rx-to-OTC switch – Rohto Algard Epinastine Eye Drops – and a direct OTC approval of Sato Pharmaceutical's Menofeminin (black cohosh) menopause treatment.

Women’s Health: Tranexamic Acid Now Available OTC In France

 
• By David Ridley

Cemag Care may be behind the recent Rx-to-OTC switch of menstrual health treatment tranexamic acid (1000mg) in France.

Perrigo: Women’s Health Innovation Must Involve Women, Right From The Start

 
• By David Ridley

“Women's health isn't a niche area," noted Perrigo’s Alison Slingsby at Lynx2Market’s PharmaSynergyOTC event in Rome. Slingsby offers advice from the firm's experience in delivering some of the most innovative women's health Rx-to-OTC switches.

More from Health

Cipla Acquires Inzpera To Grow Indian Consumer Health Offering

 
• By Tom Gallen

Cipla has paid Tata Industries around $12.5m for Inzpera Healthsciences to grow its consumer health portfolio.

Perrigo: Morning After Pill ‘Poorly Understood’ By Young Brits Having Unprotected Sex

 
• By David Ridley

Lots of young people in the UK are having unprotected sex, but are not using emergency contraception or do not understand very well how it works, according to a recent Perrigo survey.

Karo To Grow Lamisil In Europe With ‘Next Generation’ Fungal Nail Treatment

 
• By Tom Gallen

Karo will take on responsibility for the marketing, distribution and sales of Moberg’s topical onychomycosis treatment, MOB-15, under the Lamisil brand in 19 European countries.